v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jul. 31, 2026
Oct. 31, 2025
Current assets:    
Cash and cash equivalents $ 1,398 $ 1,244
Short-term investments 12,466 13,930
Prepaid expenses and other current assets 1,047 713
Total current assets 14,911 15,887
Operating lease right-of-use asset 163 193
Total assets 15,074 16,080
Current liabilities:    
Accounts payable 282 165
Accrued expenses 1,417 1,761
Operating lease liability, current 46 41
Total current liabilities 1,745 1,967
Operating lease liability, non-current 128 163
Total liabilities 1,873 2,130
Commitments and contingencies (Note 10)
Shareholders’ equity:    
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 34,584,538 and 33,013,829 shares issued and outstanding as of July 31, 2026 and October 31, 2025, respectively 346 330
Additional paid-in capital 273,489 266,508
Accumulated deficit (259,364) (251,677)
Total shareholders’ equity 14,471 15,161
Noncontrolling interest (Note 2) (1,270) (1,211)
Total equity 13,201 13,950
Total liabilities and equity 15,074 16,080
Series A Convertible Preferred Stock [Member]    
Shareholders’ equity:    
Preferred stock, value

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2026
Jul. 31, 2025
Jul. 31, 2026
Jul. 31, 2025
Income Statement [Abstract]        
Revenue
Operating expenses:        
Research and development expenses (including non-cash stock-based compensation expenses of $286, $358, $909 and $1,172, respectively) 1,326 1,055 3,686 3,929
General and administrative expenses (including non-cash stock-based compensation expenses of $380, $497, $1,218 and $1,727, respectively) 1,411 1,381 4,414 4,896
Total operating expenses 2,737 2,436 8,100 8,825
Loss from operations (2,737) (2,436) (8,100) (8,825)
Interest income 112 156 354 519
Net loss (2,625) (2,280) (7,746) (8,306)
Less: Net loss attributable to noncontrolling interest (19) (22) (59) (74)
Net loss attributable to common shareholders $ (2,606) $ (2,258) $ (7,687) $ (8,232)
Net loss per common share attributable to common shareholders:        
Basic $ (0.08) $ (0.07) $ (0.23) $ (0.25)
Diluted $ (0.08) $ (0.07) $ (0.23) $ (0.25)
Weighted average common shares outstanding:        
Basic 34,182 32,476 33,673 32,293
Diluted 34,182 32,476 33,673 32,293

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Jul. 31, 2026
Jul. 31, 2025
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (7,746) $ (8,306)
Stock option compensation to employees and directors 2,042 2,822
Stock options issued to consultants 85 77
Amortization of operating lease right-of-use asset 30 27
Change in amortization of discount on held-to-maturity securities 59 (93)
Change in operating assets and liabilities:    
Receivables 173
Prepaid expenses and other current assets (334) (155)
Accounts payable 117 (249)
Accrued expenses (344) (195)
Operating lease liability (30) (19)
Net cash used in operating activities (6,121) (5,918)
Cash flows from investing activities:    
Disbursements to acquire short-term investments (34,418) (36,700)
Proceeds from maturities of short-term investments 35,823 40,912
Net cash provided by investing activities 1,405 4,212
Cash flows from financing activities:    
Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $207 and $123, respectively 4,806 1,924
Proceeds from sale of common stock pursuant to an employee stock purchase plan 4 4
Proceeds from exercise of stock options 60 2
Net cash provided by financing activities 4,870 1,930
Net increase in cash and cash equivalents 154 224
Cash and cash equivalents at beginning of period 1,244 1,271
Cash and cash equivalents at end of period $ 1,398 $ 1,495

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL